rsv sf
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02115815)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rsv sf
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03026348 | Phase 2 | Jan 1, 2017 | Novavax |
| NCT02115815 | Phase 1 | Apr 1, 2014 | Accelovance, Compass Research, MedImmune, MRA Clinical Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Accelovance | For profit | 1 | 0 | 1 | 2014 |
| Compass Research | For profit | 1 | 0 | 1 | 2014 |
| MedImmune | For profit | 1 | 1 | 1 | 2014 |
| MRA Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Novavax | For profit | 1 | 1 | 1 | 2017 |
5 organizations
Page 1 / 1